Smith & Nephew has demonstrated a solid operational turnaround, with operating margin recovering from 5.3% in 2023Q4 to 14.5% in 2026Q2, driven by cost actions and volume recovery. Revenue growth remains steady at 4.6% in 2026Q2, supported by pricing power in high-IP devices.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 4.6% year-over-year in 2026Q2 with gross margin at 70.9%, but operating margin of 14.5% still lags peers like Stryker (19.5%), indicating structural inefficiencies.
Smith & Nephew's fourth-quarter revenue of $1.7 billion exceeded Wall Street forecasts by $20 million, driven by an 8.3% year-over-year growth.
The company is undergoing a strategic transformation under CEO Deepak Nath, with the RISE strategy aimed at accelerating revenue growth, expanding profit margins, and enhancing performance.
Smith & Nephew's 2026 guidance, unveiled at its 2025 Investor Day, indicates confidence in future growth and profitability.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.95+0.7% vs $0.94 | $3.1B-10.4% vs $3.5B |
Q2 2026 Mar 2, 2026 | $1.18+1.7% vs $1.16 | $3.2B+15.5% vs $2.8B |
Q3 2025 Aug 5, 2025 | $0.86+8.6% vs $0.79 | $3.0B+93.5% vs $1.5B |
Q1 2025 Feb 25, 2025 | $0.94+2.0% vs $0.92 | $3.0B+0.7% vs $3.0B |
SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El implante CARTIHEAL ocupará un lugar destacado en el Congreso de la Sociedad International de Regeneración de Cartílago & Preservación Articular (ICRS), que se celebrará en Oporto (Portugal) del 8 al 10 de octubre.
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata all'International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, che si terrà a Porto, in Portogallo, dall'8 al 10 ottobre.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will take center stage at this week's International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Porto, Portugal from October 8-10.
Benchmark SNN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Smith & Nephew plc (SNN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.15 | $13.08B | 21.63 | 6.09% | 10.14% | 11.84% | 2.43% | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $42.75 | $63.54B | 17.79 | 19.87% | 16.56% | 13.74% | — | |
| $51.50 | $1.54B | 21.13 | 5.16% | 5.36% | 7.07% | 1.54% | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% |
Smith & Nephew plc (SNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SNN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Smith & Nephew plc (SNN) stock FAQ — growth, dividends, profitability & financials explained
Smith & Nephew plc (SNN) reported $6.16B in revenue in fiscal year 2025. That is 237% more than the $1.83B of fiscal year 1996.
Smith & Nephew plc (SNN) grew revenue by 6.1% in fiscal year 2025, compared with the prior fiscal year.
Yes. Smith & Nephew plc (SNN) earned $625.0M in net income in fiscal year 2025 (a 10.1% net margin).
Yes. Smith & Nephew plc (SNN) pays a dividend that yields 2.43% at the current price, a moderate yield.
Smith & Nephew plc (SNN) had a return on equity (ROE) of 11.8% in fiscal year 2025. That is in line with the market's typical 10-15%.
Smith & Nephew plc (SNN) generated $852.0M in free cash flow in fiscal year 2025.
